Ultragenyx Pharmaceutical (RARE) Enterprise Value (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Enterprise Value data on file, last reported at -$406.0 million in Q1 2026.

• Enterprise Value for Q1 2026 came in at -$406.0 million, up 16.7% year-over-year; the trailing twelve-month figure through Mar 2026 was -$406.0 million (up 16.7% YoY), and the FY2025 annual result was -$673.0 million, down 11.61% from the prior year.
• Enterprise Value improved to -$406.0 million in Q1 2026 per RARE's latest filing, from -$673.0 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$406.0 million in Q1 2026 and troughed at -$888.7 million in Q3 2022.
• A 5-year average of -$578.7 million and a median of -$577.6 million in 2023 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value surged 50.25% in 2023, then slumped 39.02% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$747.8 million in 2022, then advanced by 22.75% to -$577.6 million in 2023, then slipped by 4.39% to -$603.0 million in 2024, then retreated by 11.61% to -$673.0 million in 2025, then jumped by 39.67% to -$406.0 million in 2026.
• Business Quant data shows RARE's Enterprise Value at -$406.0 million in Q1 2026, -$673.0 million in Q4 2025, and -$418.2 million in Q3 2025.